FrancophonIA/ELRC3.0 huggingface dataset:
English: Concomitant use with efavirenz containing regimens is contraindicated (see section 4.3).
Slovenian: Sočasna uporaba režimov zdravljenja, ki vključujejo uporabo efavirenza, je kontraindicirana (glejte poglavje nevirapin etravirin
English: Arm A: Exviera and ombitasvir/paritaprevir/ritonavir + RBV Arm B: Exviera and ombitasvir/paritaprevir/ritonavir
Slovenian: Skupina A: Exviera in ombitasvir/paritaprevir/ritonavir + RBV Skupina B: Exviera in ombitasvir/paritaprevir/ritonavir
English: Clinical Comments ritonavir.
Slovenian: vključno z ritonavirjem.
English: Exviera and ombitasvir/paritaprevir/ritonavir with RBV for 12 weeks n/N % 95% CI
Slovenian: Exviera in ombitasvir/paritaprevir/ritonavir z RBV 12 tednov n/N % 95 % IZ
English: Follow the dosing recommendations in Table 1.
Slovenian: Sočasna okužba s HIV-1 Upoštevajte navodila za odmerjanje v preglednici 1.
English: Dose normalized cyclosporine ratios are shown for interaction with Exviera + ombitasvir/paritaprevir/ritonavir.
Slovenian: Za odmerek normalizirana razmerja ciklosporina so prikazana za medsebojno delovanje z zdravilom Exviera + kombinacijo ombitasvir/paritaprevir/ritonavir.
English: SVR12 for genotype 1b-infected peginterferon+ribavirin-experienced subjects in PEARL II
Slovenian: SVR12 pri preiskovancih, ki so bili že zdravljeni s peginterferonom+ribavirinom, okuženih z genotipom 1b, v preskušanju PEARL II
English: ANTICONVULSANTS carbamazepine
Slovenian: ANTIEPILEPTIKI karbamazepin
English: 34 subjects (29 with HCV genotype 1a infection and 5 with HCV genotype 1b infection) were enrolled who had not received treatment for HCV infection after transplantation and had a METAVIR fibrosis score of F2 or less.
Slovenian: Vključenih je bilo 34 preiskovancev (29 z okužbo s HCV genotipa 1a in 5 z okužbo s HCV genotipa
English: Arm B: Exviera and ombitasvir/paritaprevir/ritonavir + RBV (24 weeks)
Slovenian: Skupina B: Exviera in ombitasvir/paritaprevir/ritonavir + RBV (24 tednov)
English: Croscarmellose sodium Colloidal anhydrous silica (E551) Magnesium stearate (E470b)
Slovenian: 6.1 Seznam pomožnih snovi Jedro tablete: mikrokristalna celuloza (E460(i)) laktoza monohidrat kopovidon premreženi natrijev karmelozat koloidni brezvodni silicijev dioksid (E551) magnezijev stearat (E470b)
English: Mechanism: CYP3A4 induction by phenobarbita l.
Slovenian: Mehanizem: Indukcija CYP3A4 s karbamazepino m
English: See Table 2 for guidance regarding potential drug interactions and dosing recommendations for Exviera administered with ombitasvir/paritaprevir/ritonavir.
Slovenian: Za smernice o možnih medsebojnih delovanjih zdravil in priporočila za odmerjanje zdravila Exviera, uporabljenega s kombinacijo ombitasvir/paritaprevir/ritonavir, glejte preglednico 2.
English: ↔ ethinyl estradiol
Slovenian: KG Knollstrasse
English: Ciclosporin 100 mg dosed alone and 30 mg administered with Exviera + ombitasvir/paritaprevir/ritonavir.
Slovenian: Ciklosporin 100 mg, uporabljen sam, ali 30 mg skupaj z zdravilom Exviera + kombinacijo ombitasvir/paritaprevir/ritonavir.
English: Clinical Comments possibly due to UGT1A1 inhibition by paritaprevir, ombitasvir and dasabuvir.
Slovenian: Mehanizem: Morda zavrtje UGT1A1 s paritaprevirjem, ombitasvirjem in dasabuvirjem.
English: 800 mg once daily (given at the same time)
Slovenian: 800/100 mg enkrat na dan (uporabljeno zvečer)
English: Dose normalized tacrolimus ratios are shown for interaction with Exviera + ombitasvir/paritaprevir/ritonavir.
Slovenian: Za odmerek normalizirana razmerja takrolimusa so prikazana za medsebojno delovanje z zdravilom Exviera + kombinacijo ombitasvir/paritaprevir/ritonavir.
English: Emtricitabine/ tenofovir 200 mg once daily/300 mg once daily
Slovenian: 200 mg enkrat na dan/300 mg enkrat na dan
English: In vivo drug interaction studies evaluated the net effect of the combination treatment, including ritonavir.
Slovenian: Možnost vpliva zdravila Exviera na farmakokinetiko drugih zdravil V študijah medsebojnega delovanja zdravil in vivo so ocenili neto učinek kombiniranega zdravljenja,
English: Mechanism: CYP3A4 induction by enzalutamide or mitotane.
Slovenian: Indukcija CYP3A4 z enzalutamidom ali mitotanom.
English: Arm A: Exviera and ombitasvir/paritaprevir/ritonavir + RBV
Slovenian: Skupina A: Exviera in ombitasvir/paritaprevir/ritonavir + RBV
English: ↑ dabigatran etexilate
Slovenian: ↑ dabigatran eteksilat
English: Hepatobiliary Disorders: Hepatic decompensation, hepatic failure have been observed during treatment with Exviera with ombitasvir/paritaprevir/ritonavir, with or without ribavirin (see section 4.4).
Slovenian: Neželeni učinki o katerih so poročali po prihodu zdravila na trg Bolezni jeter, žolčnika in žolčevodov: med zdravljenjem z zdravilom Exviera z ombitasvirjem/paritaprevirjem/ritonavirjem z ali brez ribavarina so opazili dekompenzacijo jeter in okvaro jeter (glejte poglavje 4.4).
English: Concomitant use is contra-indicated (see section 4.3).
Slovenian: Sočasna uporaba je kontraindicirana (glejte poglavje
English: Exviera and ombitasvir/paritaprevir/ritonavir were given for 12 weeks of treatment in combination with ribavirin.
Slovenian: Zdravilo Exviera in kombinacija ombitasvir/paritaprevir/ritonavir so dobivali 12 tednov v kombinaciji z ribavirinom.
English: − Tablet core: microcrystalline cellulose (E460(i)), lactose monohydrate, copovidone,
Slovenian: − Jedro tablete: mikrokristalna celuloza (E460(i)), laktoza monohidrat, kopovidon, premreženi natrijev karmelozat, koloidni brezvodni silicijev dioksid (E551), magnezijev stearat (E470b).
English: Treated subjects (N=394) had a median age of 54 years (range: 19 to 71); 49.0% were prior pegIFN/RBV null responders; 21.8/% were prior pegIFN/RBV partial responders; and 29.2% were prior pegIFN/RBV relapsers; 57.6% were male; 8.1% were Black; 19.8% had a body mass index of at least 30 kg/m2; 20.6% had a history of depression or bipolar disorder; 89.6% had IL28B non-CC genotype; 87.1% had baseline HCV RNA levels of at least 800,000 IU per mL; 17.8% had portal fibrosis (F2) and 14.5% had bridging fibrosis (F3); 58.4% had HCV genotype 1a infection; 41.4% had HCV genotype 1b infection.
Slovenian: Zdravljeni preiskovanci (N = 394) so bili mediano stari 54 let (razpon: od 19 do 71); 49,0 % jih predhodno ni imelo odziva na pegIFN/RBV; 21,8 % jih je predhodno imelo delen odziv na pegIFN/RBV in 29,2 % jih je predhodno imelo recidiv ob pegIFN/RBV; 57,6 % je bilo moških; 8,1 % je bilo črncev; 19,8 % jih je imelo indeks telesne mase vsaj 30 kg/m2; 20,6 % jih je imelo v anamnezi depresijo ali bipolarno motnjo; 89,6 % jih je imelo genotip IL28B ne-CC; 87,1 % jih je imelo izhodiščno koncentracijo HCV RNA vsaj 800.000 i. e./ml; 17,8 % jih je imelo portalno fibrozo (F2) in 14,5 % jih je imelo fibrozo z mostiči (F3); 58,4 % jih je imelo okužbo s HCV genotipa 1a; 41,4 % jih je imelo okužbo s HCV genotipa 1b.
English: Exviera safety and efficacy have been established in combination with ombitasvir/ paritaprevir /ritonavir with or without ribavirin.
Slovenian: Sočasna uporaba z drugimi neposredno delujočimi protivirusnimi zdravili proti HCV Varnost in učinkovitost zdravila Exviera sta bili ugotovljeni v kombinaciji z ombitasvirjem/paritaprevirjem/ritonavirjem, z ribavirinom ali brez njega.
English: Arm A: Exviera and ombitasvir/paritaprevir/ritonavir + RBV (12 weeks)
Slovenian: Skupina A: Exviera in ombitasvir/paritaprevir/ritonavir + RBV (12 tednov)
English: metabolite were not meaningfully different in subjects with hepatic impairment compared to normal control subjects (see sections 4.2, 4.4 and 4.8).
Slovenian: Vezava dasabuvirja in njegovega presnovka M1 na beljakovine v plazmi se pri preiskovancih z okvaro jeter nista bistveno razlikovali od tistih pri zdravih kontrolnih osebah (glejte poglavja 4.2, 4.4 in 5.2).
English: Subjects were randomised in a 1:1 ratio to receive Exviera and ombitasvir/paritaprevir/ritonavir with or without ribavirin for 12 weeks of treatment.
Slovenian: Preiskovanci so bili randomizirani v razmerju 1:1 za 12-tedensko zdravljenje z zdravilom Exviera in kombinacijo ombitasvir/paritaprevir/ritonavir z ribavirinom ali brez njega.
English: What Exviera contains
Slovenian: Kaj vsebuje zdravilo Exviera
English: Treated subjects (N=179) had a median age of 57 years (range: 26 to 70); 35.2% were prior pegIFN/RBV null responders; 28.5% were prior pegIFN/RBV partial responders; and 36.3% were prior pegIFN/RBV relapsers; 54.2% were male; 3.9% were Black; 21.8% had a body mass index of at least 30 kg/m2; 12.8% had a history of depression or bipolar disorder; 90.5% had IL28B non-CC genotype; 87.7% had baseline HCV RNA levels of at least 800,000 IU/mL; 17.9% had portal fibrosis (F2) and 14.0% had bridging fibrosis (F3).
Slovenian: Zdravljeni preiskovanci (N = 179) so bili mediano stari 57 let (razpon: od 26 do 70); 35,2 % jih predhodno ni imelo odziva na pegIFN/RBV; 28,5 % jih je predhodno imelo delen odziv na pegIFN/RBV in 36,3 % jih je predhodno imelo recidiv ob pegIFN/RBV; 54,2 % je bilo moških; 3,9 % je bilo črncev; 21,8 % jih je imelo indeks telesne mase vsaj 30 kg/m2; 12,8 % jih je imelo v anamnezi depresijo ali bipolarno motnjo; 90,5 % jih je imelo genotip IL28B ne-CC; 87,7 % jih je imelo izhodiščno koncentracijo HCV RNA vsaj 800.000 i. e./ml; 17,9 % jih je imelo portalno fibrozo (F2) in 14,0 % jih je imelo fibrozo z mostiči (F3).
English: Table 10 shows the SVR12 rates for treatment-experienced subjects with genotype 1-infection receiving Exviera and ombitasvir/paritaprevir/ritonavir in combination with ribavirin for 12 weeks in SAPPHIRE-II.
Slovenian: Preglednica 10 prikazuje deleže SVR12 pri že zdravljenih preiskovancih, okuženih z genotipom 1, ki so v preskušanju SAPPHIRE-II 12 tednov dobivali zdravilo Exviera in ombitasvir/paritaprevir/ritonavir v kombinaciji z ribavirinom.
English: Atazanavir/ ritonavir 300/100 mg once daily
Slovenian: atazanavir 300 mg enkrat na dan (dan ob istem času)
English: Subjects were randomised in a 1:2 ratio to receive Exviera and ombitasvir/paritaprevir/ritonavir with or without ribavirin for 12 weeks of treatment.
Slovenian: Preiskovanci so bili randomizirani v razmerju 1:2 za 12-tedensko zdravljenje z zdravilom Exviera in kombinacijo ombitasvir/paritaprevir/ritonavir z ribavirinom ali brez njega.
English: TURQUOISE-II was a randomised, global multicentre, open-label trial conducted exclusively in 380 genotype 1-infected subjects with compensated cirrhosis (Child-Pugh A) who were either treatmentnaïve or did not achieve SVR with prior treatment with pegIFN/RBV.
Slovenian: Preskušanje TURQUOISE-II je bilo globalno multicentrično, randomizirano, odprto preskušanje izključno pri 380 preiskovancih, okuženih z genotipom 1, ki so imeli kompenzirano cirozo (Child
English: PEARL-III was a randomised, global multicentre, double-blind, controlled trial conducted in 419 treatment-naïve adults with genotype 1b chronic hepatitis C virus infection without cirrhosis.
Slovenian: Preskušanje PEARL-III je bilo globalno multicentrično, randomizirano, dvojno slepo, kontrolirano preskušanje pri 419 še nezdravljenih odraslih, ki so imeli kronično okužbo z virusom hepatitisa C
English: Arm B: Exviera and ombitasvir/paritaprevir/ritonavir
Slovenian: Skupina B: Exviera in ombitasvir/paritaprevir/ritonavir
English: Patients should be informed that fatigue has been reported during treatment with Exviera in combination with ombitasvir/paritaprevir/ritonavir and ribavirin (see section 4.8).
Slovenian: 4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Bolnikom je treba povedati, da je bila med zdravljenjem z zdravilom Exviera v kombinaciji z ombitasvirjem/paritaprevirjem/ritonavirjem in ribavirinom opisana utrujenost (glejte poglavje 4.8).
English: r paritaprevir
Slovenian: ↓ paritaprevir
English: In all seven trials, the Exviera dose was 250 mg twice daily and the ombitasvir/paritaprevir/ritonavir dose was 25 mg/150 mg/100 mg once daily.
Slovenian: V vseh sedmih preskušanjih je bil odmerek zdravila Exviera 250 mg dvakrat na dan in odmerek kombinacije ombitasvir/paritaprevir/ritonavir 25/150/100 mg enkrat na dan. Preiskovanci, ki so dobivali ribavirin, so dobivali odmerek 1000 mg ribavirina na dan, če so tehtali manj kot 75 kg,
English: Plasma protein binding of dasabuvir and its M1
Slovenian: Upoštevaje vezavo na beljakovine in aktivnost M1 proti
English: No dose adjustment is necessary for emtricitabine/tenofovir and Exviera + ombitasvir/paritaprevir/ ritonavir.
Slovenian: Prilagoditev odmerka ni potrebna za emtricitabin/tenof ovir in kombinacijo Exviera + ombitasvir/paritap revir/ritonavir.
English: Exviera and ombitasvir/paritaprevir /ritonavir + ribavirin
Slovenian: Exviera in ombitasvir/paritaprevir /ritonavir + ribavirin
English: Interactions between Exviera with ombitasvir/paritaprevir/ritonavir and other medicinal products
Slovenian: Medsebojna delovanja z drugimi zdravili med uporabo zdravila Exviera s kombinacijo ombitasvir/paritaprevir/ritonavir
English: Extreme caution must be taken to avoid pregnancy in female patients and female partners of male patients when Exviera is used with ribavirin.
Slovenian: Ženske v rodni dobi/kontracepcija pri moških in ženskah Če je zdravilo Exviera uporabljeno z ribavirinom, je potrebna skrajna previdnost, da bi preprečili nosečnost bolnic in partnerk bolnikov.
English: Treatment duration was fixed in each trial and was not guided by subjects'
Slovenian: Trajanje zdravljenja je bilo v vsakem preskušanju fiksno in ga niso prilagajali koncentraciji HCV RNA pri preiskovancih (algoritem brez upoštevanja odziva).
English: CYP3A4 inhibition by ritonavir.
Slovenian: Indukcija CYP3A4 s fenobarbitalom.
English: The pharmacokinetic properties of the combination of Exviera with ombitasvir/paritaprevir/ritonavir have been evaluated in healthy adult subjects and in subjects with chronic hepatitis C. Table 17 shows mean Cmax and AUC of Exviera 250 mg twice daily with ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg once daily following multiple doses with food in healthy volunteers.
Slovenian: C. Preglednica 16 prikazuje povprečni Cmax in AUC za zdravilo Exviera 250 mg dvakrat na dan s kombinacijo ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg enkrat na dan po večkratnih odmerkih s hrano pri zdravih prostovoljcih.
English: PEARL-IV was a randomised, global multicentre, double-blind, controlled trial conducted in 305 treatment-naïve adults with genotype 1a chronic hepatitis C virus infection without cirrhosis.
Slovenian: Preskušanje PEARL-IV je bilo globalno, multicentrično, randomizirano, dvojno slepo, kontrolirano preskušanje pri 305 še nezdravljenih odraslih, ki so imeli kronično okužbo z virusom hepatitisa C
English: Table 7 shows the SVR12 rates for genotype 1-infected, treatment-naïve subjects receiving Exviera and ombitasvir/paritaprevir/ritonavir in combination with ribavirin for 12 weeks in SAPPHIRE-I.
Slovenian: Preglednica 7 prikazuje deleže SVR12 pri še nezdravljenih preiskovancih, okuženih z genotipom 1, ki so v preskušanju SAPPHIRE-I 12 tednov dobivali zdravilo Exviera in ombitasvir/paritaprevir/ritonavir v kombinaciji z ribavirinom.
English: Table 11 shows the SVR12 rates for genotype 1b-infected, treatment-experienced subjects who received Exviera and ombitasvir/paritaprevir/ritonavir with or without ribavirin for 12 weeks in PEARL II.
Slovenian: Preglednica 11 prikazuje deleže SVR12 pri že zdravljenih preiskovancih, okuženih z genotipom 1b, ki so v preskušanju PEARL II 12 tednov dobivali zdravilo Exviera in kombinacijo ombitasvir/paritaprevir/ritonavir z ribavirinom ali brez njega.
English: Treated subjects (N=380) had a median age of 58 years (range: 21 to 71); 42.1% were treatment-naïve, 36.1% were prior pegIFN/RBV null responders; 8.2% were prior pegIFN/RBV partial responders, 13.7% were prior pegIFN/RBV relapsers; 70.3% were male; 3.2% were Black; 28.4% had a body mass index of at least 30 kg/m2; 14.7% had platelet counts of less than 90 x 109/L; 49.7% had albumin less than 40 g/L; 86.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 81.8% had IL28B non-CC genotype; 24.7% had a history of depression or bipolar disorder; 68.7% had HCV genotype 1a infection, 31.3% had HCV genotype 1b infection.
Slovenian: Zdravljeni preiskovanci (N = 380) so bili mediano stari 58 let (razpon: od 21 do 71); 42,1 % jih še ni bilo zdravljenih, 36,1 % jih predhodno ni imelo odziva na pegIFN/RBV; 8,2 % jih je predhodno imelo delen odziv na pegIFN/RBV in 13,7 % jih je predhodno imelo recidiv ob pegIFN/RBV; 70,3 % je bilo moških; 3,2 % je bilo črncev; 28,4 % jih je imelo indeks telesne mase vsaj 30 kg/m2; 14,7 % jih je imelo število trombocitov manj kot 90 x 109/l; 49,7 % jih je imelo albumin manj kot 40 g/l; 86,1 % jih je imelo izhodiščno koncentracijo HCV RNA vsaj 800.000 i. e./ml; 81,8 % jih je imelo genotip IL28B
English: No increase in incidence of ALT elevations was observed with other types of systemic estrogens commonly used for hormone replacement therapy (e.g., estradiol and conjugated estrogens).
Slovenian: Z drugimi vrstami sistemskih estrogenov, ki se pogosto uporabljajo za hormonsko nadomestno zdravljenje (npr. z estradiolom in konjugiranimi estrogeni), niso opažali večje incidence zvišanj ALT. Zvišanja ALT so bila praviloma asimptomatska, so se po navadi pojavila v prvih 4
English: Table 8 shows the SVR12 rates for genotype 1b-infected, treatment-naïve subjects who received Exviera and ombitasvir/paritaprevir/ritonavir with or without ribavirin for 12 weeks in PEARL III.
Slovenian: Preglednica 8 prikazuje deleže SVR12 pri še nezdravljenih preiskovancih, okuženih z genotipom 1b, ki so v preskušanju PEARL III 12 tednov dobivali zdravilo Exviera in kombinacijo ombitasvir/paritaprevir/ritonavir z ribavirinom ali brez njega.
English: NA Clinical monitoring of
Slovenian: Kumulativne analize kliničnih preskušanj
English: Treated subjects (N=419) had a median age of 50 years (range: 19 to 70); 45.8% were male; 4.8% were Black; 16.5% had a body mass index of at least 30 kg/m2; 9.3% had a history of depression or bipolar disorder; 79.0% had IL28B non-CC genotype; 73.3% had baseline HCV RNA of at least 800,000 IU/mL; 20.3% had portal fibrosis (F2) and 10.0% had bridging fibrosis (F3).
Slovenian: Zdravljeni preiskovanci (N = 419) so bili mediano stari 50 let (razpon: od 19 do 70); 45,8 % je bilo moških; 4,8 % je bilo črncev; 16,5 % jih je imelo indeks telesne mase vsaj 30 kg/m2; 9,3 % jih je imelo v anamnezi depresijo ali bipolarno motnjo; 79,0 % jih je imelo genotip IL28B ne-CC; 73,3 %
English: As the incidence of such elevations was 26% among women taking a concomitant ethinylestradiol-containing medicine, such medicinal products are contraindicated with Exviera and ombitasvir/paritaprevir/ritonavir.
Slovenian: Ker je bila incidenca takšnih zvišanj med ženskami, ki so sočasno jemale zdravilo z etinilestradiolom, 26 %,
English: 20-120 mg once daily5
Slovenian: 20-120 mg enkrat na dan
English: Mechanism: OATP1B inhibition by paritaprevir and BCRP inhibition by dasabuvir paritaprevir, and ritonavir.
Slovenian: OATP1B s paritaprevirjem in zavrtje BCRP z dasabuvirjem, paritaprevirjem in ritonavirjem.
English: 300 mg single dose
Slovenian: Po uporabi 400-mg odmerka
English: ↔ es citalopram
Slovenian: ANTIDEPRESIVI escitalopram
English: No dose adjustment is necessary for raltegravir or Exviera + ombitasvir/paritaprevir/ ritonavir.
Slovenian: Prilagoditev odmerka ni potrebna za raltegravir ali kombinacijo Exviera + ombitasvir/paritap revir/ritonavir.
English: Caution should be used when sulfasalazine is co-administered with Exviera + ombitasvir/paritaprevir/ ritonavir.
Slovenian: Previdnost je potrebna, ko se sulfasalazin daje sočasno z zdravilom Exviera ombitasvir/paritap revir/ritonavir.
English: ↔ nor ethindrone
Slovenian: buprenorfin/nal okson
English: carbamaze pine 10, 11epoxide dasabuvir
Slovenian: Sočasna uporaba je kontraindicirana (glejte poglavje karbamazepin 10, 11-epoksid dasabuvir
English: Exviera and ombitasvir/paritaprevir/ritonavir with RBV 24-week arm
Slovenian: Exviera in ombitasvir/paritaprevir/ritonavir z RBV 24-tedenska skupina
English: MEDICINAL PRODUCTS USED IN MULTIPLE SCLEROSIS Teriflunomid e
Slovenian: ZDRAVILA, KI SE UPORABLJAJO PRI ZDRAVLJENJU MULTIPLE SKLEROZE teriflunomid Exviera + ombitasvir/p aritaprevir/ri tonavir
English: AMINOSALICYLATE Sulfasalazine
Slovenian: AUC Ctrough Klinične opombe sulfasalazin
English: The overall safety profile in HCV/HIV-1 co-infected subjects was similar to that observed in HCV mono-infected subjects.
Slovenian: Celotne varnostne značilnosti pri prejemnikih presadka, okuženih s HCV, ki so prejemali zdravilo
English: Treated subjects (N=305) had a median age of 54 years (range: 19 to 70); 65.2% were male; 11.8% were Black; 19.7% had a body mass index of at least 30 kg/m2; 20.7% had a history of depression or bipolar disorder; 69.2% had IL28B non-CC genotype; 86.6% had baseline HCV RNA levels of at least 800,000 IU/mL; 18.4% had portal fibrosis (F2) and 17.7% had bridging fibrosis (F3).
Slovenian: Zdravljeni preiskovanci (N = 305) so bili mediano stari 54 let (razpon: od 19 do 70); 65,2 % je bilo moških; 11,8 % je bilo črncev; 19,7 % jih je imelo indeks telesne mase vsaj 30 kg/m2; 20,7 % jih je imelo v anamnezi depresijo ali bipolarno motnjo; 69,2 % jih je imelo genotip IL28B ne-CC; 86,6 %
English: Mechanism: Intestinal Pgp inhibition by paritaprevir and ritonavir.
Slovenian: Mehanizem: Zavrtje P-gp v črevesju s paritaprevirjem in ritonavirjem.
English: buprenorphin e/ naloxone 4-24 mg/16 mg once daily
Slovenian: 4-24 mg/1-6 mg enkrat na dan
English: ombitas vir/parit aprevir/r itonavir
Slovenian: Exviera + paritaprevir/r itonavir
English: Exviera and ombitasvir/paritaprevir/ritonavir with RBV 12 weeks
Slovenian: Exviera in ombitasvir/paritaprevir/ritonavir z RBV 12 tednov
English: Exviera and ombitasvir/paritaprevir/ritonavir for 12 weeks With RBV
Slovenian: Exviera in ombitasvir/paritaprevir/ritonavir 12 tednov Z RBV
English: Clinical Comments paritaprevir changes during treatment with Exviera ombitasvir/paritaprevir/ ritonavir
Slovenian: Neželeni učinki pri jemanju zdravila Exviera s kombinacijo ombitasvir/paritaprevir/ritonavir
English: Exviera and ombitasvir/paritaprevir/ritonavir
Slovenian: Exviera in ombitasvir/paritaprevir /ritonavir
English: Exviera and ombitasvir/paritaprevir/ritonavir in combination with ribavirin was given for 12 weeks of treatment.
Slovenian: Preiskovanci so zdravljenje z zdraviloma Exviera in ombitasvir/paritaprevir/ritonavir v kombinaciji z ribavirinom dobivali 12 tednov.
English: Exviera and ombitasvir/paritaprevir/ritonavir in combination with ribavirin were administered for either 12 or 24 weeks of treatment.
Slovenian: Preiskovanci so zdravljenje z zdravilom Exviera in ombitasvirjem/paritaprevirjem/ritonavirjem v kombinaciji z ribavirinom dobivali 12 ali 24 tednov.
English: Duration
Slovenian: Recidiv
English: THYROID HORMONES Levothyroxin e
Slovenian: ZDRAVILA Z DELOVANJEM NA BAKTERIJO MYCOBACTERIUM TUBERCULOSIS rifampicin
English: NA No dose adjustment is necessary for paracetamol when administered with Exviera + ombitasvir/paritaprevir/ ritonavir.
Slovenian: NP Prilagoditev odmerka paracetamola ni potrebna, kadar se sočasno daje s kombinacijo Exviera + ombitasvir/paritap revir/ritonavir.
English: Efavirenz/ emtricitabine / tenofovir disoproxil fumarate mg once daily
Slovenian: efavirenz/emtri citabin/tenofovi rijev dizoproksilfum arat
English: Exviera ombitas vir/parit aprevir/r itonavir
Slovenian: Exviera + ombitasvir/ paritaprevir/r itonavir
English: Lansoprazole
Slovenian: levotiroksin
English: Exviera and ombitasvir/paritaprevir/ritonavir with RBV 12-week arm
Slovenian: Exviera in ombitasvir/paritaprevir/ritonavir z RBV 12-tedenska skupina
English: ↑ fluvastatin ↑ pitavastatin ↔ dasabuvir ↔ ombitasvir ↔ paritaprevir
Slovenian: ↔ dasabuvir ↔ ombitasvir ↔ paritaprevir esomeprazol lansoprazol
English: ↑ levothyroxine
Slovenian: ↑ furosemid
English: When starting coadministration with Exviera and ombitasvir/paritaprevir/ ritonavir, give one fifth of the total daily dose of ciclosporin once daily with ombitasvir/ paritaprevir /ritonavir.
Slovenian: Na začetku sočasne uporabe z zdravilom Exviera in kombinacijo ombitasvir/paritap revir/ritonavir dajte eno petino